Dr. John Cush RheumNow
7 years ago
CDC advises against vaping with marijuana, noting that up to 77% of 805 cases and 12 deaths from lung disease tied to vaping with THC https://t.co/dtDvMJ1dlA
The U.S. Food and Drug Administration has approved Rituxan (rituximab) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids.
This is the first approved treatment for children with vasculitis.
Dr. John Cush RheumNow
7 years ago
Survey for Rheumatologists - You would use an MRI in an RA to assess what?
Jeff Sparks jeffsparks
7 years ago
5-factor score for mortality in ANCA-associated vasculitis. I’ve never seen a worse Kaplan-Meier survival curve for those with a score of 5! @philseo #CCRwest 😬☠️ https://t.co/utK7avZ0F1
Dr. John Cush RheumNow
7 years ago
The RheumNow Podcast is up - Watch it here>> https://t.co/PolTYQqbBW or listen to the podcast on iTunes, or SoundCloud>> https://t.co/ILQQw2kpse
Dr. John Cush RheumNow
7 years ago
The RheumNow Podcast is up - discussing PSS & Cancer, SLE & narcotics, AAV & Lipids, Anakinra & NIDDM. Watch it here>> https://t.co/PolTYQqbBW or listen to the podcast on iTunes, or SoundCloud>> https://t.co/ILQQw2kpse
Dr. John Cush RheumNow
7 years ago
TIF1-γ antibodies may be associated with dermatomyositis and are found in between 13 – 31% of adults and 22 – 29% of children. TIF1-γ antibodies have a strong association with malignancy, esp in patients over the age of 39. https://t.co/0o2VfNwbZC
Dr. John Cush RheumNow
7 years ago
Dr. Rob Speira & HSS investigators will lead a multicenter, phase II, 6 mos clinical trial of anti-GM-CSF (mavrilimumab) in patients with giant cell arteritis (GCA. There is still heavy reliance on steroids in GCA; tocilizumab was FDA approved in in 2017 https://t.co/zDWgSVuXec
Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com.
Opioids are generally not indicated for pain in systemic lupus erythematosus (SLE) and other rheumatic diseases because of limited efficacy and risks for preference and adverse health effects.
A water pipe in my house broke, and I had to call for emergency plumbing service. The next day I went to the hospital, where I was on my two weeks of General Medicine inpatient attending. An elderly man was admitted, cared for, and following this patient's successful hospital discharge several days later, something occurred to me.
Dr. John Cush RheumNow
7 years ago
Question for Rheumatologists - How do you scoreboard your performance as a Rheumatologist?
A double-blind, placebo-controlled clinical trial of low-dose IL-2 in patients with systemic lupus erythematosus (SLE) has shown that low-dose IL-2 induced was clinically effective while expandng regulatory T cells and NK cells, which may benefit immune homeostasis in SLE patients.
Dr. John Cush RheumNow
7 years ago
41 participants with RA and T2D were randomised to recv anakinra or a TNFi; RA dz activity decreased in both groups over 6 mos. Anakinra significantly improved A1C at 3 and 6 mos, but TNFi did not. https://t.co/UIBsRjMbKR
